BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

William Xu

Session 13 – Advances in Cell & Gene Therapy

Date:29 July (Friday)
Time:  12:20 – 13:50 (GMT+8)

William Xu

Medical Strategy Director
IQVIA RDS PTY. LIMITED

 

Dr. William Xu is the Director and Medical Strategy Lead for IQVIA’s APAC Cell and Gene Therapy (CAGT) Center of Excellence. He is the CAGT subject matter expert and provides scientific, clinical and operational advice to both internal stakeholders and sponsors to help develop innovative, data-driven and patient-centric solutions for CAGT trials. William holds a Master of Science in Biotechnology from University of New South Wales, Australia and a Bachelor of Clinical Medicine from Shanghai Jiao Tong University, China. Prior to joining IQVIA, he worked in Roche/Genetech as therapeutic and clinical operations lead for 16 years and also practiced as a urologist before joining industry. 
 

Speech title & Synopsis

Promise Fulfilled? The next decade of cell, gene, and RNA therapies

The 2020s were always going to be the era when the full commercial promise of cell, gene and RNA therapies, known collectively as advanced therapies, was to be realised and the pandemic, by hugely accelerating the development and uptake of mRNA vaccines, has been transformative for RNA.

We are at a pivotal moment in the development of these therapies; the next decade will bring enormous changes to usher cell, gene and RNA therapies into the pharmacotherapeutic mainstream. 

​​